Business
Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom
Company's validated test available in the UK following implementation of UKHSA CTDA Regulations SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Co-Diagnostics,
About this update from Co-diagnostics, Inc.
[{"type":"text","content":"Company's validated test available in the UK following implementation of UKHSA CTDA Regulations\n\n\nSALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 2-Gene multiplex test has been validated according to the United Kingdom Health Security Agency's (\"UKHSA\") Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (\"CTDA\") and is available for sale in the UK under the Regulation.\n\n \n \n \n \n \n \n\n \nThe UKHSA is the agency responsible for planning, preventing, and responding to external health threats, replacing Public Health England earlier this year. CTDA amends a previous regulation to require that SARS-CoV-2 test devices must be approved by the Secretary of State before they are placed on market or put into service, and specifies the performance requirements that such devices must meet. Co-Diagnostics' test has completed the validation required by the CTDA and received approval to be sold according to the amended Regulation, and has been validated for use with several sample types, including saliva.\n\"We are pleased that our 2-gene multiplex SARS-CoV-2 test has been approved for sale according to the UK's high standard of quality and performance,\" remarked Dwight Egan, CEO of Co-Diagnostics. \"Since the pandemic began, we have been on the forefront of providing gold-standard PCR solutions across the world, including Europe. We believe that each additional validation of our Company's testing technology continues to demonstrate the quality of our patented CoPrimer™ platform, and the valuable role we have been fortunate enough to play in improving the quality of life for people affected by the pandemic through providing accurate, reliable, and cost-effective COVID-19 testing products.\"\nThe Company's test is available for sale through Client Life Science, Co-Diagnostics' authorized distributor in the UK.\nAbout Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid mole...